Spectrum Pharmaceuticals (SPPI) to Release Quarterly Earnings on Thursday

Spectrum Pharmaceuticals (NASDAQ:SPPI – Get Rating) will announce its earnings results before the market opens on Thursday, August 11th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Spectrum Pharmaceuticals (NASDAQ:SPPI – Get Rating) last announced its earnings results on Thursday, May 12th. The biotechnology company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.09. On average, analysts expect Spectrum Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Spectrum Pharmaceuticals Price Performance

Shares of NASDAQ SPPI opened at $0.88 on Thursday. The company has a 50 day simple moving average of $0.82 and a two-hundred day simple moving average of $0.86. Spectrum Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $3.26. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.38 and a current ratio of 2.38. The company has a market capitalization of $158.48 million, a price-to-earnings ratio of -1.00 and a beta of 2.01.

Wall Street Analyst Weigh In

SPPI has been the topic of a number of recent analyst reports. JMP Securities reiterated a “buy” rating and set a $4.00 price target on shares of Spectrum Pharmaceuticals in a report on Tuesday, June 7th. StockNews.com upgraded shares of Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 23rd. Cantor Fitzgerald reiterated a “neutral” rating on shares of Spectrum Pharmaceuticals in a report on Wednesday, June 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Spectrum Pharmaceuticals in a report on Friday, May 27th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $6.00.

Institutional Investors Weigh In On Spectrum Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in SPPI. Mirabella Financial Services LLP purchased a new stake in Spectrum Pharmaceuticals in the first quarter worth approximately $27,000. Ergoteles LLC purchased a new position in shares of Spectrum Pharmaceuticals during the 1st quarter worth $386,000. Acadian Asset Management LLC boosted its stake in shares of Spectrum Pharmaceuticals by 1,355.2% during the 1st quarter. Acadian Asset Management LLC now owns 421,867 shares of the biotechnology company’s stock worth $543,000 after acquiring an additional 392,877 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Spectrum Pharmaceuticals by 5.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 432,628 shares of the biotechnology company’s stock worth $559,000 after acquiring an additional 22,726 shares during the last quarter. Finally, Panagora Asset Management Inc. boosted its stake in shares of Spectrum Pharmaceuticals by 40.4% during the 1st quarter. Panagora Asset Management Inc. now owns 849,041 shares of the biotechnology company’s stock worth $1,095,000 after acquiring an additional 244,100 shares during the last quarter. Hedge funds and other institutional investors own 58.51% of the company’s stock.

Spectrum Pharmaceuticals Company Profile

(Get Rating)

Spectrum Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma.